Kamada (KMDA) Other Non-Current Assets (2012 - 2025)
Kamada (KMDA) posted quarterly Other Non-Current Assets of $1.4 million for Q4 2025, up 1163.39% year-on-year from $112000.0 in Q4 2024, and up 1163.39% on a QoQ basis from $112000.0 in Q4 2024.
Kamada (KMDA) Other Non-Current Assets (2012 - 2025) Analysis & Trends
Kamada (KMDA) has reported Other Non-Current Assets for 14 consecutive years, with $1.4 million the latest figure, recorded in Q4 2025.
- Quarterly Other Non-Current Assets rose 1163.39% year-over-year to $1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (up 1163.39% YoY) and the FY2025 annual result came in at $1.4 million, up 1163.39% from the prior year.
- Other Non-Current Assets improved to $1.4 million in Q4 2025 per KMDA's latest filing, from $112000.0 in the prior quarter.
- Over the last five years, Other Non-Current Assets for KMDA reached as high as $153.7 million in Q4 2021 and fell as low as $112000.0 in Q4 2024.
- A 5-year average of $70.3 million and a median of $7.6 million in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2021 — Other Non-Current Assets soared 9668.79% — and 2022, when it sank 95.07%.
- Year by year, Other Non-Current Assets stood at $153.7 million in 2021, then plunged by 95.07% to $7.6 million in 2022, then plunged by 93.27% to $510000.0 in 2023, then plunged by 78.04% to $112000.0 in 2024, then surged by 1163.39% to $1.4 million in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $1.4 million, $112000.0, and $510000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.42 Mn |
| Dec 31, 2024 | 112,000.00 |
| Dec 31, 2023 | 510,000.00 |
| Jun 30, 2023 | 143.99 Mn |
| Mar 31, 2023 | 145.31 Mn |
| Dec 31, 2022 | 7.58 Mn |
| Sep 30, 2022 | 148.62 Mn |
| Jun 30, 2022 | 150.45 Mn |
| Mar 31, 2022 | 151.86 Mn |
| Dec 31, 2021 | 153.66 Mn |
| Sep 30, 2021 | 3.38 Mn |
| Jun 30, 2021 | 3.41 Mn |
| Mar 31, 2021 | 3.18 Mn |
| Dec 31, 2020 | 1.57 Mn |
| Sep 30, 2020 | 1.08 Mn |
| Jun 30, 2020 | 1.06 Mn |
| Mar 31, 2020 | 1.05 Mn |
| Dec 31, 2019 | 352,000.00 |
| Sep 30, 2019 | 178,000.00 |
| Jun 30, 2019 | 174,000.00 |